Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment
Ugo Giovanni Falagario(Ospedali Riuniti di Foggia), Peter Wiklund(Unknown), Giorgio Gandaglia(Vita-Salute San Raffaele University), Tobias Nordström(Karolinska Institutet), Alexander Valdman(Karolinska Institutet), Ash Tewari(Royal Free London NHS Foundation Trust), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alberto Martini(The University of Texas MD Anderson Cancer Center), Francesco Pellegrino, Anna Lantz(Mount Sinai Hospital), Vincenza Conteduca(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Markus Aly(Karolinska University Hospital), Olof Akre(Unknown), Lars Björnebo(Karolinska Institutet), Thorgerdur Palsdottir(Karolinska Institutet), Martin Eklund(Karolinska Institutet), Ahmad Abbadi, Giuseppe Carrieri(University of Foggia), Francesco Montorsi(Vita-Salute San Raffaele University), Henrik Grönberg(Karolinska Institutet)
Cited by 3
Related Papers
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
|Nature Genetics|2018|1k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656